Table 1.
Laboratory test | Value | Normal range |
---|---|---|
Serum Chemistry | ||
Sodium | 139 | 136-144 mmol/L |
Potassium | 3.5 (L) | 3.6-5.1 mmol/L |
Chloride | 106 | 101-111 mmol/L |
Carbon dioxide | 27 | 22-32 mmol/L |
Blood urea nitrogen | 12 | 8-20 mg/dL |
Glucose | 104 (H) | 65-99 mg/dL |
Calcium | 8.9 | 8.4-10.2 mg/dL |
Creatinine | 1.17 | .60-1.30 mg/dL |
Total protein | 8.3 (H) | 6.1-7.9 g/dL |
Albumin | 4.2 | 3.5-5.4 g/dL |
Total bilirubin | 1.7 (H) | .2-1.0 mg/dL |
Albumin | 4.2 | 3.5-5.4 g/dL |
Lactate dehydrogenase | 4671 (H) | 313-618 unit/L |
Alkaline phosphatase | 52 | 38-126 52 unit/L |
Aspartate aminotransferase | 74 (H) | 15-41 unit/L |
Alanine transaminase | 34 | 5-35 unit/L |
Magnesium a | 1.6 (L) | 1.8-2.4 mg/dL |
Phosphorous a | 4.9 | 3.1-5.6 mg/dL |
Procalcitonin a | .13 (L) | .50-2.00 ng/dL |
Creatine kinase a | 222 (H) | 55-170 unit/L |
Ammonia | <9 (L) | 11-35 mcmol/L |
Iron | 189 (H) | 28.0-170.0 mcg/dL |
Total iron binding capacity | 395 (H) | 162-344 mcg/dL |
Ferritin | 444.00 (H) | 6.00-137.00 ng/mL |
Transferrin | 265 | 206-381 mg/dL |
Free T3 a | 1.68 (L) | 2.18-3.98 pg/mL |
Thyroid stimulating hormone a | .868 | .358-3.740 mclU/mL |
Free T4 a | 1.16 | .80-2.00 ng/dL |
Hemoglobin A1C a | 4.1% | ≤5.6% |
Pregnancy | Negative | N/A |
Acetaminophen level a | 11.0 (H) | ≤10.0 mcg/mL |
Salicylate a | <1.0 (L) | 10.0-30.0 mg/dL |
Ethyl alcohol a | <10 | N/A |
% Serum ethyl alcohol a | <.010 | N/A |
Haptoglobin | <8.0 (L) | 30.0-200.0 mg/dL |
C-reactive protein a | 5.40 | ≤9.00 mg/L |
Serum C3 (complement) | 75.0 (L) | 90.0-180.0 mg/dL |
Serum C4 (complement) | 6.6 (L) | 10.0-40.0 mg/dL |
Cardiac a | ||
Brain natriuretic peptide | 13.8 | ≤100.0 pg/mL |
Troponin-I | .014 | .000-.034 ng/mL |
Hematology | ||
White blood cells (WBCs) | 6.9 | 4.2-10.2 thou/mcL |
Red blood cells (RBCs) | 2.85 (L) | 3.50-5.50 x10^6/ mcL |
Hemoglobin | 8.5 (L) | 12.0-16.0 g/dL |
Hematocrit | 25.9% (L) | 36.0-48.0% |
Mean corpuscular volume (MCV) blood | 90.9 | 78.0-98.0 fL |
Mean corpuscular hemoglobin (MCH) blood | 29.8 | 25.0-35.0 pg |
MCH concentration | 32.8 | 30.0-36.0 g/dL |
Red cell distribution width (RDW) | 21.4% (H) | 12.4-16.6% |
RDW standard deviation | 62.7 (H) | 37.0-54.0 fL |
Nucleated RBCs | .39 | .00-5.00x10^3/ mcL |
Platelet count | 6 (L) | 140-400 thou/mcL |
Absolute neutrophils | 3.1 | 1.8-7.1 thou/mcL |
Absolute lymphocytes | 3.47 | 1.30-5.94 thou/mcL |
Absolute reticulocytes | 349.7 (H) | 30.0-90.0 thou/mcL |
Immature reticulocyte fraction | 40.9% | N/A |
Segmented neutrophils | 46.1% | N/A |
Lymphocytes | 51.0% | N/A |
Monocytes | 1.0% | N/A |
Eosinophils | 1.9% | N/A |
Nucleated RBCs | 5.70 (H) | .00-1.00/100 WBC |
Erythrocyte sedimentation rate | 36 (H) | 0-20 mm/hr |
Schistocytes | Few | N/A |
Coagulation | ||
Fibrinogen level | 244 | 208-475 mg/dL |
Active partial thrombin time | 30.3 | 23.2-34.1 sec |
International normalized ratio | 1.11 | .85-1.16 |
Prothrombin time | 14.1 | 11.7-14.5 sec |
D-dimer, quantitative a | 4.45 (H) | .00-.44 mcg FEU/mL |
Russell viper venom | 25.0 (L) | 28.3-43.1 sec |
Immunology a | ||
Cardiolipin antibody (Ab), IgA | <2.0 | <20.0, units not specified |
Cardiolipin Ab, IgG | <2.0 | <20.0, units not specified |
Cardiolipin Ab, IgM | <2.0 | <20.0, units not specified |
Anti-cardiolipin IgG | <1.6 | ≤19.9 GPL U/mL |
Anti-cardiolipin IgM | 1.0 | ≤19.9 MPL U/mL |
Beta-2-glycoprotein I (GPI) IgG | <1.4 | ≤19.9 unit/mL |
Phosphatidylserine IgG | <10 | <10 unit/mL |
Phosphatidylserine IgM | <25 | <25 unit/mL |
Phosphatidylserine IgA | <20 | <20 unit/mL |
Beta-2-GPI IgG | <2.0 | <20.0 unit/mL |
Beta-2-GPI IgM | <2.0 | <20.0 unit/mL |
Beta-2-GPI IgA | <2.0 | <20.0 unit/mL |
Antimicrosomal Ab | 95.6 (H) | ≤60 unit/mL |
Antinuclear Ab (ANA) | Positive (A) | Negative |
ANA titer | Positive 1:320 (A) | Negative |
ANA pattern | Speckled | N/A |
Anti-double stranded DNA Ab | 1 | ≤4 IU/mL |
Anti-Smith | 0.2 | ≤.9 AI |
Anti-RNP | <0.2 | ≤.9 AI |
Anti-SSA | >8.0 (H) | ≤.9 AI |
Anti-SSB | >8.0 (H) | ≤.9 AI |
Homocysteine | 7.4 | 4.0-15.5 mcmol/L |
SARS-CoV-2 total ab | 1310.00 (H) | ≤.99 unit not specified |
ADAMTS-13 activity | <3% (C) | 68-163% |
ADAMTS-13 inhibitor | 12.0 (H) | <4 Bethesda units |
Cerebrospinal fluid studies b | ||
Glucose | 72 | 40-75 mg/mL |
Protein | 52.5 (H) | 15-45 mg/100 mL |
WBCs | 0 | <5/mL |
RBCS | 0 | <5/mL |
UA | Unremarkable | |
Infectious studies | ||
RPR screen a | Negative | N/A |
Hepatitis (Hep) A-IgM antibody a | Negative | N/A |
Hep B surface antigen a | Negative | N/A |
Hep B core-IgM antibody a | Negative | N/A |
Hepatitis C antibody | Negative | N/A |
Human immunodeficiency virus (HIV) antibody/antigen | Negative | N/A |
Tuberculosis quantiferon gold | Negative | N/A |
Coronavirus SARS-CoV-2 (COVID-19) PCR test | Negative | N/A |
Meningitis/encephalitis panel | Negative | N/A |
Escherichia Coli K1 CSF | ||
Haemophilus influenzae CSF | ||
Listeria monocytogenes CSF | ||
Neisseria meningitidis CSF | ||
Streptococcus agalactiae CSF | ||
Streptococcus pneumoniae CSF | ||
Cytomegalovirus (CMV) CSF | ||
Enterovirus (EV) CSF | ||
Herpes-simplex Virus-1 (HSV-1) CSF | ||
Herpes-simplex Virus-2 (HSV-2) CSF | ||
Human Herpesvirus-6 (HHV-6) CSF | ||
Human parechovirus (HPeV) CSF | ||
Varicella zoster virus (VZV) CSF | ||
Cryptococcus neoformans/Gatti CSF | ||
Respiratory pathogen panel | Negative | N/A |
aspecimen collected after first day (24 h) of admission.
bObtained at outside hospital.
Abbreviations: (L): low, (H): high, (A): abnormal, (C): critical.